Loading...
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study
BACKGROUND: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical and biochemical response induced by originator af...
Saved in:
| Published in: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8239954/ https://ncbi.nlm.nih.gov/pubmed/34249147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562848211023384 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|